No products in the cart.
IGH rearrangements including translocations and fusions involving a variety of other genes is a common event. Numerous studies have shown that these rearrangements, with, for example MYC, MAF, CCND1 and MALT1 to be implicated in numerous hematological tumors including lymphomas, leukemia’s and multiple myeloma1,2,3,4.
FOR DISTRIBUTION OUTSIDE THE UNITED STATES ONLY
|Download OUS Datasheet|
IVD is NOT for Sale in the United States but may be available in certain countries outside of the United States, please contact your local distributor for more information.
1. Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Ishigaki T, Sasaki K, Watanabe K, Nakamura N, Toyota S, Kobayashi H, Tohda S. Cancer Genet Cytogenet. 2010 Aug;201(1):62-5.
2. t(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G, Raderer M, Chott A. Blood 2003; 101: 2335-2339.
3. Long-range oncogenic activation of Igh–c-myc translocations by the Igh 3′ regulatory region. Monica Gostissa, Catherine T. Yan, Julia M. Bianco, Michel Cogné, Eric Pinaud & Frederick W. Alt. Nature 462, 803-807 (10 December 2009)
4. Fonseca et al. (2004). Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res. 64:1546.
5. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.